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ABSTRACT
PATIENT VERSUS PHYSICIAN PERCEPTIONS OF PROGNOSIS AND END-OF-LIFE
OUTCOMES IN ACUTE LEUKEMIA.
Sophia Shimer and Kerin Adelson. Section of Medical Oncology, Department of Internal
Medicine, Yale School of Medicine, New Haven, CT.

Background: Acute leukemia poses unique challenges for prognostication. In many
cases, cure is possible but unlikely and treatment is risky. Little is known about how
patients perceive their prognosis. The purpose of this study was to assess prognostic
understanding and end-of-life outcomes in patients with acute leukemia.

Methods: In this observational study, we surveyed patients admitted with acute
leukemia and their treating hematologists. We elicited patient preferences for
prognostic information and asked whether goals of care discussions had occurred. We
then compared patient vs physician perceptions of treatment goals, chance of cure,
expected survival, and chance that treatment would lessen suffering. Patient-physician
concordance was assessed with kappa statistics. After a minimum follow-up of 1 year,
we compared perceptions of prognosis to actual survival outcomes. Finally, we
measured healthcare utilization at the end of life.

Results: We enrolled 76.6% (105/137) of eligible patients. We restricted our analysis to
the 90 patient-physician dyads in which both parties completed a survey. Although

83.5% of patients wanted to be told their prognosis, only 56.8% recalled their physician
disclosing treatment response rates. Most patients (82.2%) and physicians (78.9%)
shared a goal of cure. However, they differed significantly in their perceptions of the
chance of cure. Both non-relapsed and relapsed patients were more likely than their
physicians to report a > 80% chance of cure (57.9% vs 5.2% for non-relapsed, p < 0.001;
38.7% vs 0.0% for relapsed, p < 0.001). Among those willing to estimate survival time,
75.7% of patients vs 28.4% of physicians estimated > 5 years (p < 0.001). Patients were
also more likely to report a > 80% chance that treatment would lessen suffering (50.6%
vs 21.6%, p < 0.001). Patient-physician concordance was poor for both chance of cure (κ
= 0.05) and chance of lessening suffering (κ = 0.02). When prognostic perceptions were
compared to actual survival outcomes, 54.1% of patients and 33.8% of physicians
overestimated survival. The analysis of healthcare utilization at the end of life revealed
high rates of in-hospital death (50.0%); hospitalization (93.8%) and ICU admission
(54.2%) within 30 days of death; and hospice enrollment within 7 days of death (37.5%).

Conclusions: Most patients overestimate their prognosis compared to their
hematologist’s assessment and actual survival outcomes. This finding is significant
because, while optimism can help with coping, there is also a risk of unrealistic
expectations influencing treatment decisions and patterns of care.
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INTRODUCTION
Most patients with cancer want to know their prognosis and participate actively in
decision-making regarding their care.1-3 The American Society of Clinical Oncology has
issued consensus guidelines recommending that oncologists broach discussions about
prognosis and goals of care earlier in the course of illness, not just at the end of life.4,5
Despite the growing call from both patients and oncologists for improved
communication about prognosis, many patients hold inaccurate—and usually overly
optimistic—perceptions of their prognosis. Previous research has shown that advanced
cancer patients overestimate their likelihood of cure and long-term survival,
misunderstand treatment intent to be curative when it is palliative, and do not
acknowledge the terminal nature of their illness.1,6-9

Most of the previous research on prognostic understanding was carried out in solid
tumor populations.1,6-9 There is comparatively little data for hematologic malignancies.
A few small studies have found that patients undergoing hematopoietic stem cell
transplant overestimate their prognosis.10-13 El-Jawahri et al. found that 77.6% of
transplant recipients overestimated chance of cure compared to their oncologist’s
assessment. This was despite a reported desire for prognostic information: 88.9% of
patients said it was “extremely” or “very” important to learn about their prognosis, and
74.4% wanted “as much information as possible” about their prognosis.10 Grulke et al.
reported that transplant recipients’ prognostic estimates correlated with their
psychological symptom burden, but not with objective disease- or treatment-related
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variables.11 More recently, El-Jawahri et al. conducted another study in older adults
with acute myeloid leukemia (AML), finding that these patients overestimated both
their likelihood of cure and the risk of treatment-related mortality.14 However,
prognostic understanding in the acute leukemia population remains insufficiently
studied.

Acute leukemias differ from solid tumors in key ways that make researching patient and
physician understanding of prognosis challenging. First, there is a difference in
curability: whereas advanced solid tumors are usually unambiguously incurable, in acute
leukemia there is often a real possibility of cure that must be balanced against a high
risk of complications.15 Second, there is a difference in illness trajectory: whereas solid
tumors usually have a gradual onset and progress linearly, acute leukemias often
present suddenly and follow an unpredictable course marked by intermittent periods of
acute exacerbation and intensive treatments.16-18 A patient’s condition can deteriorate
suddenly and dramatically due to infection or hemorrhage, contributing to uncertainty
in prognostication and timing of goals of care discussions.17

Why does prognostic understanding matter? Evidence is accumulating that prognostic
misperceptions can influence treatment preferences and ultimately patterns of care. In
a large cohort of patients with metastatic solid tumors, Weeks et al. demonstrated that
overestimation of survival was associated with a preference for, and ultimately receipt
of, more aggressive treatment.19 In the Coping with Cancer study, Enzinger et al. found
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that patients who overestimated their survival were less likely to complete advance care
planning such as do-not-resuscitate orders and living wills.1

Little is known about the link between prognostic understanding and patterns of care in
hematologic malignancies. In a large national survey in which hematologic oncologists
were asked to identify barriers to providing quality end-of-life care for patients with
blood cancers, the top reported barrier was unrealistic patient expectations.20 This
topic merits further investigation because hematologic malignancy patients have
especially high rates of healthcare utilization and aggressive treatment at the end of life.
Compared to their counterparts with solid tumors, patients with hematologic
malignancies are more than twice as likely to die in the hospital and more likely to
undergo hospitalization, ICU admission, and chemotherapy within 30 days of death.21,22
They are less likely to receive palliative care or hospice services, and when they do
enroll in hospice it is often just days before death; this is particularly true for patients
with leukemia.23-25

Here, we report results of an observational study examining prognostic understanding
and end-of-life outcomes in acute leukemia. Our study differs from previous work in the
hematologic malignancy population in four key ways. First, we include patients at all
stages of the acute leukemia disease trajectory (including new diagnosis, remission, and
relapsed/refractory disease). Previous studies focused more narrowly on either newly
diagnosed patients or those undergoing transplant.10-14,26 Recently, Kayastha et al.
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examined the impact of relapse status on patient-reported outcomes such as quality of
life and distress, but they did not assess prognostic understanding.27 Further research is
needed to more completely capture how prognostic understanding varies at different
stages of illness, for example after relapse.

Second, we evaluate the various components of prognostic understanding in richer
detail. Experts in patient-physician communication have identified 5 distinct elements
of prognostic understanding: current state of disease, life expectancy, curability, decline
trajectory, and available treatment options.28 Our study recognizes this
multidimensionality by asking not only about chance of cure but also about other
elements that are less commonly studied, such as chance that treatment will reduce
suffering. Third, we compare patient perceptions of prognosis to both physician
opinions and actual survival outcomes. Finally, we assess healthcare utilization at the
end of life to explore the link between prognostic perceptions and patterns of care.

STATEMENT OF PURPOSE
The purpose of this observational study was to assess how well patients with acute
leukemia at Yale-New Haven Hospital understand their prognosis by comparing patients’
perceptions to their physicians’ opinions and to actual end-of-life outcomes.

Specific aims

5

Aim 1: To describe patient and physician (treating hematologist) perceptions of
prognosis and goals of care.
Aim 2: To measure patient-physician concordance regarding prognosis and goals of
care.
Aim 3: To identify patient demographic and clinical factors associated with prognostic
understanding.
Aim 4: To compare perceptions of prognosis to actual survival outcomes.
Aim 5: To assess healthcare utilization at the end of life.

Hypothesis
Our hypothesis was that patient-physician concordance regarding prognosis would be
poor, and that patients would be more optimistic than their physicians.

METHODS
Participants
Patients eligible for this study were adults with acute leukemia (including acute myeloid
leukemia and acute lymphoblastic leukemia) admitted to Smilow Cancer Hospital at
Yale-New Haven, the clinical arm of the Yale Cancer Center. Exclusion criteria included
not speaking English, serious cognitive impairment, and inability to communicate
verbally with researchers.

Study design and procedures
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This study was approved by the Yale Institutional Review Board. We identified
potentially eligible patients by screening the inpatient hematologic malignancy service
census. Consecutively eligible patients were invited to participate and provided written
informed consent. Enrollment occurred between August 2015 and November 2017.

Enrolled patients completed a survey (Appendix 1) administered in-person by a
researcher. For newly diagnosed patients, we waited at least 1 week after the date of
diagnosis to administer the survey in order to allow time for cytogenetic testing and
discussions about prognosis with a hematologist. Then, we asked each patient’s
treating hematologist to complete a short survey (Appendix 2) assessing the individual
patient’s prognosis and goals of care, using a subset of the items on the patient survey.
We conducted an initial medical record review at the time of enrollment to abstract
clinical factors. Finally, in December 2018, after a minimum of 1 year of follow-up, we
conducted another medical record review to assess survival outcomes and healthcare
utilization at the end of life.

Measures
Perceptions of prognosis and goals of care. Several items assessing prognostic
perceptions were adapted from the Coping with Cancer study, a large, multisite,
prospective study of psychosocial factors in patients with advanced solid tumors.1,29
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We asked patients whether they would want to be told their prognosis and elicited their
preferences for involvement in treatment decision-making. We also asked whether they
recalled their physician discussing expected survival time, treatment response rates, or
end-of-life preferences.

We asked both patients and their physicians to complete the following 6 survey items,
so that patient vs physician responses could be compared. 1) We asked participants to
rate current health status as “relatively healthy,” “seriously ill,” or “terminally ill.” 2) We
asked whether the goal of current treatment was “cure,” “extend life,” or “lessen
suffering.” 3) Likelihood of cure, 4) likelihood of extending life, and 5) likelihood of
lessening suffering were each rated on a 5-point scale (0-20%, 21-40%, 41-60%, 61-80%,
and 81-100%). 6) Finally, we asked participants to estimate survival time, with options
ranging from months to years.

Demographic factors. Patients reported age, sex, race, ethnicity, marital status, income,
education, religion, and level of religiosity. Health insurance type was obtained from
medical records.

Clinical factors. Type of leukemia, relapse status, and transplant status were identified
by medical record review. Health-related quality of life was assessed using the
Functional Assessment of Cancer Therapy—Leukemia (FACT-Leu) Version 4
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instrument.30 We also assessed Eastern Cooperative Oncology Group (ECOG)
performance status for all patients.31

Survival outcomes and healthcare utilization at the end of life. At the end of the followup period, survival outcomes were ascertained from medical records. Overall survival
was measured from the time of enrollment to death or censoring. For patients who had
died, we also obtained information on place of death, hospice enrollment, receipt of
palliative care consultation, hospitalization within 30 days of death, ICU admission
within 30 days of death, receipt of chemotherapy or targeted therapy within 14 days of
death, CPR or intubation within 30 days of death, and transfusion of red blood cells or
platelets within 7 days of death. We chose these particular outcomes because they
have previously been identified as standard quality measures for end-of-life care in the
hematologic malignancy population.20

Statistical analysis
For the purpose of sample size calculation, we chose a primary outcome of patientphysician discordance regarding likelihood of cure. We calculated a minimum sample
size of 76 patients to have 80% power to detect a >1 point difference on the 5-point
likelihood-of-cure scale, using a 5% significance level. We posited that a >1 point
difference was clinically relevant, as this was in line with how previous studies have
defined prognostic discordance.10,32,33
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We calculated descriptive statistics for baseline patient characteristics, including means
or medians for continuous variables and frequencies for categorical variables. For our
analysis comparing patient vs physician perceptions, we used two methods. First, we
reported frequency distributions of patient vs physician responses and used chi-square
or Fisher’s exact tests to determine whether these distributions differed significantly.
Second, we quantified the level of concordance between patient and physician
responses using Cohen’s kappa statistics. Kappa statistics were interpreted using
benchmark ranges described by Landis and Koch; kappa values < 0.20 indicate poor or
slight concordance, and kappa values of 0.8 to 1.0 indicate almost perfect
concordance.34

We used logistic regression to explore demographic and clinical factors associated with
patient-physician prognostic concordance. For these analyses, prognostic concordance
was defined as patient and physician rating the likelihood of cure within 1 point of each
other on the 5-point likelihood-of-cure scale.

Survival analysis was conducted using the Kaplan-Meier method and log-rank tests for
significance. Analyses were performed using SAS software (version 9.4; SAS Institute
Inc., Cary, NC). All reported p values are two-sided. P values < 0.05 were considered
significant.

Contributions
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Sophia Shimer was responsible for study conception and design, under the guidance of
Kerin Adelson. Sophia Shimer wrote the protocol, surveys, and consent forms;
completed the IRB submission; conducted recruitment and survey administration for the
majority of study participants; and completed all data abstraction from medical records.
Sophia Shimer and Maureen Canavan were responsible for data analysis and
interpretation, with Maureen Canavan primarily providing guidance for kappa statistics
and logistic regression models. Steven Gore provided expert advice on interpretation of
leukemia-related clinical factors. Renee Capasso, Tehreem Babar, and Sara
Tannenbaum assisted with recruitment and survey administration.

RESULTS
Participant characteristics
We enrolled 105 of 137 eligible patients (76.6% participation rate). We restricted our
analysis to the 90 patient-physician pairs in which both parties completed a survey.
Baseline patient characteristics are listed in Table 1. In terms of demographics, patients
were predominantly white (77/90, 85.6%) and Christian (73/90, 81.1%). The median age
was 59.5 years (range 22 to 86), and half the patients were female (45/90, 50.0%). In
terms of clinical factors, most patients (73/90, 81.1%) had a diagnosis of AML, with the
remainder having ALL. Patients at all stages of illness were represented: 41.1% were
newly diagnosed, 31.1% were in remission, and 27.8% had relapsed or refractory
disease. In addition, a third of patients (30/90, 33.3%) had either previously undergone
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hematopoietic stem cell transplant or were admitted to undergo transplant at the time
of enrollment.
Table 1: Baseline patient characteristics (n = 90)
Characteristic
Age: median (range), years
Sex
Male
Female
Race
White
Non-white
Ethnicity
Hispanic or Latino
Non-Hispanic or Latino
Type of leukemia
AML
ALL
Disease status at enrollment
New diagnosis
Remission
Relapse/refractory
Number of relapses
0
≥1
Transplant status
No HSCT
Current admission for HSCT
Past HSCT
Insurance
Private
Medicare
Medicaid
Education (n = 88)
≤ High school
Some college or trade school
≥ College degree
Income (n = 75)
< $19,999
$20,000 - 79,999
$80,000 -139,999
> $140,000
Marital status
Married or living with partner

No.
%
59.5 (22-86)
45
45

50.0
50.0

77
13

85.6
14.4

8
82

8.9
91.1

73
17

81.1
18.9

37
28
25

41.1
31.1
27.8

58
32

64.4
35.6

60
17
13

66.7
18.9
14.4

44
33
13

48.9
36.7
14.4

22
27
39

25.0
30.7
44.3

9
28
18
20

12.0
37.3
24.0
26.7

53

58.9

12
Never married
Separated, divorced, or widowed
Religion
Christian
Other
ECOG PS (n = 87)
0
1 or 2
3 or 4

15
22

16.7
24.4

73
17

81.1
18.9

44
29
14

50.6
33.3
16.1

Abbreviations: AML, acute myeloid leukemia; ALL, acute
lymphoblastic leukemia; HSCT, hematopoietic stem cell
transplant; PS, performance status

Patient perceptions of goals of care discussions
Most patients (71/85, 83.5%) wanted to be told their prognosis. Most patients (77/90,
85.6%) also wanted to be involved in treatment decision-making, although a minority
(13/90, 14.4%) preferred to leave all treatment decisions up to their physicians. When
asked to reflect on past conversations with their hematologist, only 56.8% (50/88) of
patients recalled discussing chance of response to treatment, 28.1% (25/89) recalled
discussing expected survival time, and 21.8% (19/87) recalled discussing end-of-life
preferences.

Patient-physician comparisons
Patients were more optimistic than their physicians in assessing several different
components of prognosis. When asked to describe their current health status at the
time of enrollment, only 9.0% (8/89) of patients responded “terminally ill,” compared to
16.7% (15/90) of their physicians (p = 0.03; Figure 1).
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p = 0.03

Figure 1. Patient vs physician perceptions of current health status.
Abbreviation: MDs, physicians.

When asked to select the primary goal of their current treatment, most patients (74/90,
82.2%) and physicians (71/90, 78.9%) shared a goal of cure (Figure 2). However, they
differed significantly in their perceptions of the likelihood of cure. The majority of
patients (45/88, 51.1%) thought their chance of cure was > 80%, compared to only a
small minority (3/90, 3.3%) of physicians (p < 0.001; Figure 3). Table 2 shows a crosstabulation of paired patient-physician responses estimating chance of cure, illustrating
how few pairs gave matching responses. Kappa statistics confirmed that patientphysician concordance regarding chance of cure was poor (κ = 0.05; 95% CI, -0.02 to
0.13).

Figure 2. Patient vs physician perceptions of primary goal of care.
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p < 0.001

Figure 3. Patient vs physician perceptions of the likelihood of cure. Patients at all stages of
illness (relapsed and non-relapsed) are included.

Table 2: Patient-physician concordance regarding chance of cure (n = 88 pairs)A
Physician response
Patient response
0-20%
21-40%
41-60%
61-80%
81-100%
0-20%
5
2
0
1
0
21-40%
2
1
1
1
0
41-60%
5
2
2
1
0
61-80%
9
3
4
4
0
81-100%
8
13
15
6
3
Total
29
21
22
13
3
κ coefficient (95% CI)
0.05 (-0.02 to 0.13)

Total
8
5
10
20
45
88

This table shows a cross-tabulation of paired patient-physician responses estimating
chance of cure.
A

Patients estimated chance of cure more optimistically than their physicians at all stages
of illness. This became apparent when patients were stratified by relapse status (Table
3). In the non-relapsed group, 57.9% (33/57) of patients vs only 5.2% (3/58) of their
physicians reported a > 80% chance of cure (p < 0.001). In the relapsed group, 38.7%
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(12/31) of patients vs 0.0% (0/32) of their physicians reported a >80% chance of cure (p
< 0.001).
Table 3: Patient vs physician perceptions of chance of cure, stratified by relapse status
Non-relapsed
Relapsed
(n = 58)
(n = 32)
Chance of
Patients
Physicians
Patients
Physicians
p-value
p-value
cure (%)
(%)
(%)
(%)
(%)
0-20
5.3
19.0
16.1
59.4
21-40
3.5
22.4
9.7
25.0
41-60
12.3
32.8
< 0.001
9.7
12.5
< 0.001
61-80
21.1
20.7
25.8
3.1
81-100
57.9
5.2
38.7
0.0

Patients were also more optimistic than their physicians about the likelihood that
treatment would extend their life (Figure 4) and the likelihood that treatment would
lessen their suffering (Figure 5). Only 41.1% (37/90) of surveyed patients were willing to
estimate how much longer they had to live; the rest responded “don’t know,” “in God’s
hands/up to fate,” or left the question blank. Among those willing to provide an
estimate, 75.7% (28/37) of patients vs 28.4% (21/74) of physicians estimated a survival
time of > 5 years (p < 0.001; Figure 6). Patient-physician concordance was poor for
chance of extending life (κ = 0.08; 95% CI, -0.04 to 0.20), chance of lessening suffering (κ
= 0.02; 95% CI, -0.08 to 0.12), and estimated survival time (κ = 0.08; 95% CI, -0.08 to
0.24).
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p < 0.001

Figure 4. Patient vs physician perceptions of the likelihood that treatment will extend life.

p < 0.001

Figure 5. Patient vs physician perceptions of the likelihood that treatment will lessen suffering.

p < 0.001

Figure 6. Patient vs physician estimates of survival time.
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Exploratory analyses of associations between prognostic concordance and other
covariates
We conducted an exploratory analysis with the goal of identifying demographic and
clinical factors associated with patient-physician prognostic concordance. However, no
associations emerged as significant in our bivariate or multivariable models. Specifically,
there were no associations between prognostic concordance and age, sex, race,
insurance type, education, religion, ECOG performance status, or relapse status.
Prognostic concordance was also not significantly associated with health-related quality
of life as measured by FACT-Leu.

Comparison of estimated vs actual survival time
By the end of the follow-up period, 53.3% (48/90) of patients in the cohort had died.
The median overall survival of the entire cohort was 18 months (95% CI, 13 to 30
months). Figure 7 shows Kaplan-Meier survival plots stratified by relapse status; nonrelapsed patients lived significantly longer than relapsed patients (median survival, 23
months vs 7 months, p = 0.002).

For participants who had been willing to estimate survival time on the baseline survey (n
= 37 patients and n = 74 physicians), we compared estimated vs actual survival (Figure
8). Only 8.1% (3/37) of patients and 14.9% (11/74) of physicians provided an accurate
estimate (actual survival was within the time range estimated). Both patients and
physicians were more likely to overestimate than underestimate survival, but patients
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were especially optimistic: 54.1% (20/37) of patients vs 33.8% (25/74) of physicians
overestimated, and 5.4% (2/37) of patients vs 12.2% (9/74) of physicians
underestimated (p < 0.001).

Figure 7: Overall survival stratified by relapse status at the time of enrollment. Shaded areas
represent Hall-Wellner 95% confidence bands.
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Figure 8: Accuracy of patients’ and physicians’ survival time estimates, as compared to actual
survival. “Longer follow-up time needed to evaluate accuracy” means that the patient was still
alive at the end of the follow-up period but had not yet attained the estimated survival time.

Healthcare utilization at the end of life
Table 4 shows healthcare utilization at the end of life for the 48 patients who died
during follow-up. Half of these patients (24/48, 50.0%) died in the hospital as opposed
to at home or in hospice. Although 47.9% (23/48) of those who died received hospice
services, transition to hospice usually only occurred when death was imminent: only
10.4% (5/48) enrolled in hospice more than 7 days before dying. Within 30 days of
death, 93.8% (45/48) of patients were hospitalized, 54.2% (26/48) were admitted to the
ICU, 33.3% (16/48) were intubated, and 10.4% (5/48) received CPR. Within 14 days of
death, 41.7% (20/48) of patients received chemotherapy or targeted therapy. Within 7
days of death, 66.7% (32/48) of patients received a red blood cell or platelet transfusion.
The majority (31/48, 64.6%) of patients who died received a palliative care consultation.
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Table 4: Healthcare utilization at the end of life (n = 48 patients)
Characteristic
Place of death
Hospital
Hospice (home services or inpatient facility)
Home without hospice
Hospice enrollment
> 7 days before death
≤ 7 days before death
Hospitalization within 30 days of death
ICU admission within 30 days of death
CPR within 30 days of death
Intubation within 30 days of death
Chemotherapy or targeted therapy within 14 days of death
Transfusion within 7 days of death
Received palliative care consult

No. of patients

%

24
23
1

50.0
47.9
2.1

5
18
45
26
4
16
20
32
31

10.4
37.5
93.8
54.2
8.3
33.3
41.7
66.7
64.6%

Abbreviations: ICU, intensive care unit; ED, emergency department; CPR, cardiopulmonary
resuscitation

DISCUSSION
Several key findings emerged from this study of prognostic understanding and end-oflife outcomes in the acute leukemia population. First, more patients wanted to know
their prognosis than recalled discussing it with their hematologist, indicating a gap
between patients’ desire for and receipt of prognostic information. Second, we found
substantial discrepancies between patient and hematologist perceptions of prognosis.
Patients tended to be more optimistic: they were less likely to label themselves
terminally ill, more likely to perceive a high chance of cure, and more likely to estimate a
survival time of > 5 years. Third, both patients and physicians overestimated survival,
with patients being especially optimistic. Fourth, healthcare utilization at the end of life
was high.
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Our finding of a large patient-physician discrepancy in perceived chance of cure is in line
with other recent studies in the hematologic malignancy population.10,14 In our study’s
acute leukemia population, 51.1% of patients vs 3.3% of physicians thought their chance
of cure was > 80%; similarly, in a recent study of older adults with AML, El-Jawahri et al.
reported that 52% of patients vs 0% of physicians thought their chance of cure was >
75%.14

One unique aspect of our study was that we assessed multiple dimensions of prognostic
understanding, asking not only about chance of cure but also about current health
status, goals of care, estimated survival time, and likelihood that treatment would
extend life or lessen suffering. Perceptions of anticipated suffering have been
particularly overlooked in previous research. In our study, patients were more likely
than their physicians to think that the treatment they were receiving would reduce their
suffering. This discrepancy suggests that patients may be minimizing the risk of side
effects and overestimating how treatment would alleviate their symptom burden. In
fact, physical and psychosocial symptom burdens often increase during active
treatment.27,35 Misperceptions about anticipated suffering are especially important to
recognize in patients for whom goals of care have shifted from extending life toward
preserving quality of life.

In our study, the gap between patient and physician understanding was most striking in
the relapsed group. Over a third of relapsed patients vs none of their physicians
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thought chance of cure was > 80%. Inaccurate prognostic perceptions likely have a
greater impact on treatment decisions in the relapsed population—especially in
relapsed patients who are also older and frail. Young, relatively fit patients with newly
diagnosed leukemia would likely choose the same treatment—intensive induction
chemotherapy—whether they inaccurately believed their chance of cure to be > 80% or
accurately understood it to be 30-40%. On the other hand, for older, medically frail
patients with relapsed disease deciding whether to pursue further lines of cure-directed
therapy, the difference between inaccurately believing chance of cure to be > 80% and
accurately understanding it to be < 10% could be quite consequential. Unrealistic
expectations may predispose vulnerable patients toward overly aggressive and perhaps
futile treatment. Thus, the high rate of prognostic overestimation among relapsed
patients is particularly concerning.

Our findings raise the question of whether oncologists in clinical practice should be
aiming for perfect patient-physician agreement on prognosis. Is patients’ relative
optimism always problematic? Optimism can be part of a constructive coping strategy,
and may help patients persevere through prolonged, socially isolating hospitalizations
and intensive, high-toxicity treatments.36 Oncologists often worry that disclosing a poor
prognosis will take away hope or otherwise cause psychological harm.20,37 We did not
find any significant association between prognostic understanding and quality of life,
including emotional well-being, but we did not specifically ask about loss of hope.
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The existing literature on this topic has yielded mixed results. In a study on the
psychological impact of acute leukemia, Gheihman et al. found that while depression
was common and related to physical symptom burden, hopelessness was less common
and associated with older age and lower self-esteem. Perceived poor communication
with healthcare providers was not independently associated with hopelessness.16 In the
Coping with Cancer study, prognostic disclosures were not associated with emotional
distress or harm to the patient-physician relationship.1 However, in another study of
patients with advanced gastrointestinal cancer, accurate prognostic understanding was
associated with worse quality of life and anxiety.38 Finally, in the hematologic
malignancy population, El-Jawahri and colleagues reported that more accurate
prognostic understanding was associated with worse quality of life and increased
depression.10,14 Given the lack of consensus, a cautious approach to prognostic
disclosure is warranted. In their conversations with patients, oncologists must balance
maintaining hope with the need to set realistic expectations to enable informed
decision-making.

The intensity of healthcare utilization at the end of life in our cohort matched or
exceeded that found in previous studies in the hematologic malignancy
population.22,24,25 In our cohort, within the last month of life almost all patients were
hospitalized, over half were admitted to the ICU, and many received chemotherapy.
While we observed a relatively high rate of hospice utilization (47.9%), enrollment was
usually late, occurring just days before death. Several factors may contribute to this
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pattern. On the one hand, it may reflect a sudden deterioration in clinical status and
transition to end-of-life care. Alternatively, it may point toward barriers to timely
hospice enrollment such as a lack of blood product transfusion services. In a study of
Medicare beneficiaries with leukemia, transfusion dependence was associated with
higher rates of hospice utilization but shorter lengths of stay.39 Indeed, in our cohort
the majority of patients (66.7%) received a transfusion within a week of death; perhaps
some deferred hospice enrollment because they would be unable to receive supportive
transfusions. This highlights the need for hospice services that allow transfusions as a
component of comfort care.

Interestingly, in our cohort we also observed a higher rate of utilization of palliative care
services compared to previous reports. In our sample, the majority (64.6%) of patients
who died received a palliative care consult, compared to only 16.2% of a cohort of older
adults with AML and 33% of patients in a heterogeneous cohort of hematologic
malignancy patients, both at academic institutions.22,24 These variable rates may reflect
institution-level differences in patterns of palliative care referral.

Our study has several limitations. First, the cross-sectional design of our survey did not
allow for tracking changes in prognostic understanding over time. A longitudinal study
with surveys at different time points would be better suited for identifying clinical
events along the disease trajectory that trigger changes in understanding. Second, our
small sample size consisting of predominantly white patients limited our ability to detect
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associations between demographic and clinical variables and prognostic understanding
in our exploratory analyses. Previous studies in solid tumor populations have found that
patients who are nonwhite, older, or non-native English speakers are more likely to
report a prognosis or treatment intent that is discordant from their physician’s.7,32
Third, we did not assess whether patients knew that their hematologist’s opinion
differed from their own; in other words, we did not distinguish between known and
unknown discordance. Gramling et al. found that unknown discordance was more
common in the advanced cancer population and posited that it is a marker of poor
patient-provider communication.32 Fourth, in our analysis of healthcare utilization, we
did not distinguish between chemotherapy given with curative vs palliative intent, which
limited our ability to assess the appropriateness of high rates of chemotherapy
administration near death.

Finally, this study did not directly evaluate patient-physician communication. Thus, the
actual prognostic discussion remains a “black box,” and we are not able to determine
the exact locus of the discrepancy in patient-physician perceptions. Are physicians not
disclosing the prognosis, or are patients simply not hearing it, perhaps because they are
too overwhelmed to listen? Future work will include audio recordings of prognostic
discussions to crack open this “black box.”

In summary, this observational study of prognostic understanding in the acute leukemia
population revealed that most patients strikingly overestimate their prognosis
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compared to their hematologist's assessment and to actual end-of-life outcomes. This
study went beyond previous work by assessing more dimensions of prognostic
understanding and comparing patients at different stages of illness. Our findings are
significant because, while optimism can help with coping, there is also a risk of
unrealistic expectations influencing treatment decisions, especially after relapse. Future
work will focus on two areas: 1) examining actual patient-physician prognostic
conversations and 2) further exploring associations between prognostic understanding
and patterns of care.
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APPENDIX
Appendix 1: Patient Survey

STUDY ID #: _________
Assessment of Prognostic Understanding and Perceived Goals of Care in Patients with
Leukemia
PATIENT SURVEY

Please circle your answers.
A: THE BRIEF ILLNESS PERCEPTION QUESTIONNAIRE (B-IPQ)
For the following questions, please circle the number that best corresponds to your views now.
1. How much does
0 1 2 3 4 5 6 7 8 9 10
your illness affect
No effect at all
Severely affects
your life?
my life
2. How long do you
think your illness
will continue?
3. How much control
do you feel you
have over your
illness?
4. How much do you
think your
treatment can help
your illness?
5. How much do you
experience
symptoms from
your illness?
6. How concerned are
you about your
illness?
7. How well do you
feel you understand
your illness?
8. How much does
your illness affect
you emotionally?
(e.g., does it make

0
A very short
time

1

2

3

4

5

6

7

8

9 10
For the rest of
my life

0
Absolutely no
control

1

2

3

4

5

6

7

8

9 10
Extreme
amount of
control

0 1
Not at all

2

3

4

5

6

7

8

9

10
Extremely
helpful

0 1
No symptoms
at all

2

3

4

5

6

7

8

9

10
Many severe
symptoms

0 1
Not at all
concerned

2

3

4

5

6

7

8

9

10
Extremely
concerned

0 1
Don’t
understand at
all
0 1
Not at all
affected
emotionally

2

3

4

5

6

7

8

9

10
Understand
very clearly

2

3

4

5

6

7

8

9 10
Extremely
affected
emotionally
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you angry, scared,
upset or
depressed?)
B: CONTROL PREFERENCES SCALE (CPS)
1. In terms of making decisions about your health care with your doctor, which ONE of the
following best describes how you would like to make these decisions?
(1) Make the final selection about which treatment I will receive
(2) Make the final selection after seriously considering my doctor's opinion
(3) Have my doctor and I share responsibility for deciding what treatment is best
(4) Have my doctor make the final decision but consider my opinion
(5) Leave all decisions regarding treatment to my doctor
C: UNDERSTANDING OF PROGNOSIS
1. How would you describe your current health status?
(1) Relatively healthy
(2) Seriously ill but not terminally ill
(3) Seriously and terminally ill
2. Did your cancer doctor discuss how long you may have to live?
(1) Yes
(2) No
3. If your doctor knew how long you had left to live, would you want him or her to tell
you?
(1) Yes
(2) No
4. Based on your understanding about what your doctors have told you about your cancer,
your health in general, and the treatments you are receiving, how long do you think you
have to live?
(1) Up to 3 months
(2) 3 to 6 months
(3) 6 to 12 months
(4) 1-2 years
(5) 2-5 years
(6) At least 5 years
(7) In God’s hands/Up to fate
(8) Don’t know
5. What is the basis of this estimate of how long you have to live?
(1) My cancer doctor told me
(2) A palliative care specialist told me
(3) Other clinic staff told me
(4) My personal belief, having to do with religion
(5) My personal belief, not having to do with religion
(6) Other (SPECIFY): __________________________________________________
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D: PERCEPTION OF GOALS OF CARE AND TREATMENT PREFERENCES
1. Did your cancer doctor talk to you about your goals of care? A goals of care
conversation includes discussions about the likely outcome of your illness, possible
treatment options, and clarifies things that are most important to you given your cancer
diagnosis.
(1) Yes
(2) No
2. What is the primary goal of your current medical treatment?
(1) To cure my cancer
(2) To extend my life as long as possible without cure
(3) To lessen suffering as much as possible
3. How likely do you think you are to be cured of cancer?
(1) Very likely
(2) Likely
(3) Unlikely
(4) Very unlikely
4. If you had to estimate your chance of being cured of cancer, what would it be?
(1) 0%
(2) 1% to 20%
(3) 21% to 40%
(4) 41% to 60%
(5) 61% to 80%
(6) 81% to 100%
5. How likely do think it is that your current treatment will extend your life?
(1) Very likely
(2) Likely
(3) Unlikely
(4) Very unlikely
6. If you had to estimate the chance that your current treatment will extend your life, what
would it be?
(1) 0%
(2) 1% to 20%
(3) 21% to 40%
(4) 41% to 60%
(5) 61% to 80%
(6) 81% to 100%
7. How likely do you think it is that your current treatment will lessen your suffering?
(1) Very likely
(2) Likely
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(3) Unlikely
(4) Very unlikely
8. If you had to estimate the chance that your current treatment will lessen your suffering,
what would it be?
(1) 0%
(2) 1% to 20%
(3) 21% to 40%
(4) 41% to 60%
(5) 61% to 80%
(6) 81% to 100%
9. Did your cancer doctor discuss specific numbers about your chance of responding to
your current treatment?
(1) Yes
(2) No
10. Did your cancer doctor talk to you about medications or treatments that could help with
the side effects of your cancer treatments or help with the side effects of the cancer
itself?
(1) Yes
(2) No
11. Did your cancer doctor talk to you about your preferences for cancer treatment?
(1) Yes
(2) No
12. Overall, do you agree that the treatments you’ve gotten for your cancer match your
preferences?
(1) Strongly Disagree
(2) Disagree
(3) Neither agree nor disagree
(4) Agree
(5) Strongly agree
13. What is more important to you: treatment that focuses on quality of life or treatment
that focuses on lengthening life?
(1) Focus on quality of life
(2) Focus on lengthening life
14. If a therapy that lengthened your life resulted in a worse quality of life, would you still
choose it?
(1) Yes
(2) No
(3) Don’t know
15. Do you think your doctor would offer you treatment that would not help you just
because he or she thought you wanted it?
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(1) Yes
(2) No
16. Do you think your doctor would offer you treatment that would not help you but would
help others with the information its effect on you would provide?
(1) Yes
(2) No
17. Have you and your doctor discussed any particular wishes you have about the care you
would want to receive if you were dying?
(1) Yes
(2) No
18. Do you have a signed Living Will or Durable Power of Attorney for health care, both, or
neither?
(1) Yes, Living Will
(2) Yes, Durable Power of Attorney
(3) Yes, both
(4) Neither
(5) Don’t know
19. Have you completed a Do Not Resuscitate (DNR) order?
(1) Yes
(2) No
(3) Don’t know
20. Do you think it would be a bad thing for a person to die in the ICU versus elsewhere (e.g.
home, hospital, hospice)?
(1) Yes
(2) No
21. Would you want the doctors here to do everything possible to keep you alive even if you
were going to die in a few days anyway?
(1) Yes
(2) No
E: RELIGIOUSNESS
1. What is your religious preference?
(1) Agnostic
(2) Atheist
(3) Buddhist
(4) Catholic
(5) Christian
(6) Hindu
(7) Jewish
(8) Muslim
(9) Protestant
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(10) Other (SPECIFY): ________________________________
2. How religious/spiritual do you consider yourself to be?
(1) Not at all
(2) A little
(3) Somewhat
(4) Very
(5) I don’t know
3. To what extent do your religious beliefs or activities help you cope with or handle your
illness?
(1) Not at all
(2) To a small extent
(3) To a moderate extent
(4) To a large extent
(5) It is the most important thing that keeps me going
(6) Don’t know
F: DEMOGRAPHICS
1. How old are you? _____ years old
2. What is your gender?
(1) Male
(2) Female
(3) Other (SPECIFY): _________________________________________________
3. Are you now married, living with a partner in a marriage-like relationship, widowed,
divorced, separated, or never married?
(1) Married
(2) Living with partner
(3) Widowed
(4) Divorced
(5) Separated
(6) Never married
4. Do you have health insurance now? (If NO, skip to question 6)
(1) Yes
(2) No
5. What type of health insurance coverage do you currently have?
(1) Private health insurance or HMO
(2) Medicare
(3) Medicaid
(4) Veteran’s administration (VA) health care
(5) Other government health plan
(6) Other non-government health plan
(7) Don’t know

36

6. What is the highest grade of school you have completed?
(1) Never attended/Kindergarten only
(2) Less than Junior High school (grades 1-8)
(3) Less than High School (grades 8-11)
(4) High School graduate or GED
(5) Some college, no degree
(6) Trade/Vocational school
(7) College degree
(8) Graduate School
7. How often do you need to have someone help you when you read instructions,
pamphlets, or other written material from your doctor or pharmacy?
(1) Never
(2) Rarely
(3) Sometimes
(4) Often
8. Are you Hispanic or Latino?
a. Yes
b. No
9. What is your race?
a. White
b. Black or African American
c. Asian
d. American Indian/Alaskan Native
e. Native Hawaiian/Pacific Islander
f. More than one race (SPECIFY): ___________________________________
g. Other (SPECIFY): _________________________________________
10. Which of the following categories best describes the total amount of money that came
into your household last year before taxes?
a. $ 0-19,999
b. $ 20,000-39,999
c. $ 40,000-59,999
d. $ 60,000-79,999
e. $ 80,000-99,999
f. $ 100,000-119,000
g. $ 120,000-139,000
h. $ 140,000 and over
i. Don’t know
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Appendix 2: Physician Survey
Study ID #: _________

Physician Assessment of Prognosis and Primary Goal of Care

Please circle your answers.
1. How would you describe this patient’s current health status?
(1) Relatively healthy
(2) Seriously ill but not terminally ill
(3) Seriously and terminally ill
2. How long do you think this patient has to live?
(1) Up to 3 months
(2) 3 to 6 months
(3) 6 to 12 months
(4) 1-2 years
(5) 2-5 years
(6) At least 5 years
(7) In God’s hands/Up to fate
(8) Don’t know
3. What is the primary goal of this patient’s current medical treatment?
(1) To cure the cancer
(2) To extend life as long as possible without cure
(3) To lessen suffering as much as possible
4. How likely do you think this patient is to be cured of cancer?
(1) Very likely
(2) Likely
(3) Unlikely
(4) Very unlikely
5. Please estimate the chance that this patient will be cured of cancer.
(1) 0%
(2) 1% to 20%
(3) 21% to 40%
(4) 41% to 60%
(5) 61% to 80%
(6) 81% to 100%
6. How likely do think it is that this patient’s current treatment will extend his or her life?
(1) Very likely
(2) Likely
(3) Unlikely
(4) Very unlikely
7. Please estimate the chance that this patient’s current treatment will extend his or her
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life.

(1)
(2)
(3)
(4)
(5)
(6)

0%
1% to 20%
21% to 40%
41% to 60%
61% to 80%
81% to 100%

8. How likely do you think it is that this patient’s current treatment will lessen his or her
suffering?
(1) Very likely
(2) Likely
(3) Unlikely
(4) Very unlikely
9. Please estimate the chance that this patient’s current treatment will lessen his or her
suffering.
(1) 0%
(2) 1% to 20%
(3) 21% to 40%
(4) 41% to 60%
(5) 61% to 80%

